Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Xiaoyan Xing, PhD
CONTACT
Fei Ma, PhD
CONTACT
Lead
Qilu Pharmaceutical Co., Ltd.
This is a randomized, open-label, multicenter Phase 3 study to evaluate ESG401 versus Investigator's Choice Chemotherapy (ICC) as first-line treatment in subjects with unresectable recurrent or metastatic triple-negative breast cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted